References
- Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvein TK, Schnitzer TJ, for the VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520–8
- Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999;282:1929–33
- Watson DJ, Harper SE, Zhao PL, Hui Q, Bolognese JA, Simon TJ. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis. Arch Intern Med 2000;160:2998–3003
- Lanza FL, Rack MF, Simon TJ, Quan H, Bolognese JA, Hoover ME, Wilson FR, Harper SE. Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen. Aliment Pharmacol Ther 1999;13:761–7
- Hawkey CJ. Nonsteroidal anti-inflammatory drug gastropathy. Gastroenterology 2000;119:521–35
- Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxi-city of nonsteroidal antiinflammatory drugs. N Engl J Med 1999;340:1888–99
- MacDonald TM, Morant SV, Robinson GC, Shield MJ, McGilchrist MM, Murray FE, McDevitt DG. Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study. BMJ 1997;315:1333–7
- Bolten WW, Lang B, Wagner AV, Krobot KJ. Kosequenzen und Kosten der NSA-Gastropathie in Deutschland [in German]. Akt Rheumatol 1999;24:127–34
- Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient-relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988;15:1833–40
- Bundesanzeiger (German Federal Gazette) No. 229: 4 December, 1998:16884
- Steinfeld S, Poriau S. Patient and physician satisfaction with rofecoxib in osteoarthritis: results of the EVA (Experience with VIOXX in Arthritis) survey. Curr Med Res Opin 2001;17:1–7
- Physician’s Circular for VIOXX® 12.5 mg and VIOXX® 25 mg. MSD Sharp & Dohme GmbH, November 1999
- Hawkey C, Laine L, Simon T, Beaulieu A, Maldonado-Cocco J, Acevedo E, Shahane A, Quan H, Bolognese J, Mortensen E. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis. A randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy Multinational Study Group. Arthritis Rheum 2000;43: 370–7
- Schwartz JI, Malice MP, Lasseter KC, Holmes GB, Gottesdiener KM, Brune Kt. Effec of rofecoxib, celecoxib, and naproxen on blood pressure and urinary sodium excretion in elderly volunteers. Ann Rheum Dis 2001;60 (Suppl 1):227 (Abstr)
- Knott L. Treating osteoarthritis in practice – the TOP study. Curr Med Res Opin 2000;16:147–52
- Laine L, Bombardier C, Ramey DR, Watson DJ, Pellissier JM, Reicin A. Less use of gastrointestinal (GI) protective agents and GI-related procedures with rofecoxib vs. naproxen in the VIGOR (VIOXX GI Outcomes Research) Study. Ann Rheum Dis 2001;60 (Suppl 1):278 (Abstr)
- Bombardier C, Laine L, Carides GW, Pellisier JM, Ramey DR, Watson DJ, Reicin A. Less healthcare resource utilization for perforations, ulcers and bleeds with rofecoxib vs. naproxen in the VIGOR (VIOXX GI Outcomes Research) Study. Ann Rheum Dis 2001;60 (Suppl 1):81 (Abstr)
- Jonsson B, Haglund U. Economic burden of NSAID-induced gastropathy in Sweden. Scand J Gastroenterol 2001;7:775–9